initial public offerings (IPO) of Takuni Group Public Company Limited (TAKUNI) and CCN-Tech Public Company Limited (CCN) in late 2014 has revealed that Chupong, then CGH executive responsible for the
Limited (TAKUNI) and CCN-Tech Public Company Limited (CCN) in late 2014 has revealed that {A}, then CGH executive responsible for the underwriting of TAKUNI and CCN securities, used nominee accounts to
According to the findings of SEC inspection on the operation of SKFM whose main business is private fund management, in 2018 Mr. King, CEO and fund manager of the company at the time, acted in the following manners: (1) funneling damage incurred from investment among the clients of private funds by making cross-trade transactions of shares under trading suspension (SP) sign on a continual basis from 2015 to 2017; (2) managing private funds without taking the cli...
Bangkok, February 17, 2016 ? The SEC is seeking public comments on proposed amendments to the initial public offering (IPO) rules. The amendments aim to facilitate sufficient share distribution to
shareholding (Pre-emptive Right) and will inform the Stock Exchange of Thailand, instantly. Please be informed accordingly. Respectfully yours, -Weera Louwitawas- ( Mr. Weera Louwitawas ) Chief Executive Officer
sincerely, -signed- (Mr. Chaiwat Kovavisarach) President and Chief Executive Officer The Secretary to the Board of Directors Division Tel: 0 2335 4638 Fax: 0 2016 3982 Preliminary Information of the Employee
Wongsinudom Chairman and Independent Director - - - 1,200,0501/ 0.18 2. Mr. Kitti Jivacate Director 1 0.00 Director and Chief Executive Officer 372,858,9632/ 55.85 3. Miss Nilrat Jarumanopas Director 1 0.00
Mr. Noppakrit Nithilertvijit Mr. Noppakrit Nithilertvijit, Chief Executive Officer for the operation of Successmore Being Public Company Limited ("SCM"), shall be liable for SCM's
sincerely, Miss Supamas Isarabhakdi Chief Executive Officer DOD Biotech Public Company Limited
Baht 939.87 million and new share issuance for capital increase of Baht 55 million. Please be informed accordingly. Yours sincerely, Miss Supamas Isarapakdi Chief Executive Officer DOD Biotech Public